Interestingly, an R77Q mutation frequently found in patients with gastric cancer enhances the catalytic capacity of AARS1 [16], while mutating other essential lactate-binding residues to alanine simultaneously eliminates AARSs’ binding to lactate [45]. This evidence concerns the gene AARS1 and gastric cancer.